A 28-year-old woman from Delhi presents with a 6-month history of photosensitive malar rash, arthralgia affecting small joints of hands, and persistent oral ulcers. Laboratory investigations show ANA positive (1:640, homogeneous pattern), anti-dsDNA antibodies 180 IU/mL (normal <70), and low C3 (65 mg/dL, normal 90–180). Urinalysis shows 2+ proteinuria and RBC casts. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has SLE with clear diagnostic criteria (ANA+, anti-dsDNA+, low complement, photosensitivity, arthralgia, oral ulcers) and evidence of **active lupus nephritis** (2+ proteinuria, RBC casts, low C3 indicating complement consumption). The critical next step is renal biopsy. ## Why Renal Biopsy is the Most Appropriate Next Step **Key Point:** According to ACR/EULAR 2019 guidelines and Harrison's Principles of Internal Medicine (21e, Ch. 319), **renal biopsy is strongly recommended in all patients with SLE who have clinical evidence of active nephritis** (proteinuria >500 mg/day, active urinary sediment with RBC casts) before initiating targeted immunosuppression. **High-Yield:** The ISN/RPS classification of lupus nephritis (Classes I–VI) directly determines the immunosuppressive regimen: - **Class I/II** (mesangial): Hydroxychloroquine ± low-dose steroids; no aggressive immunosuppression - **Class III/IV** (focal/diffuse proliferative): Induction with high-dose steroids + mycophenolate mofetil OR cyclophosphamide - **Class V** (membranous): Steroids + MMF or calcineurin inhibitors - **Class VI** (sclerotic): Supportive care; immunosuppression unlikely to benefit ### Rationale for Correct Answer (Renal Biopsy First) 1. **Class-specific therapy**: Without biopsy, the clinician cannot distinguish Class II (requiring minimal immunosuppression) from Class IV (requiring aggressive induction), leading to either under- or over-treatment 2. **Prognostic information**: Biopsy provides activity and chronicity indices that guide long-term management and predict renal outcomes 3. **Guideline mandate**: ACR 2012 and EULAR 2019 guidelines explicitly state that renal biopsy should be performed in all patients with clinical lupus nephritis before initiating class-specific therapy 4. **Safety**: Starting empiric high-dose immunosuppression without histological confirmation risks unnecessary toxicity if the class does not warrant it ## Why Not the Other Options? | Option | Reason Incorrect | |--------|-----------------| | **A – HCQ + prednisolone, repeat in 2 weeks** | Hydroxychloroquine is appropriate as background therapy, but initiating prednisolone without knowing the nephritis class is premature; biopsy should precede class-specific immunosuppression | | **C – MMF 1 g BD immediately** | MMF is first-line induction for Class III/IV nephritis, but cannot be initiated appropriately without biopsy confirming the class | | **D – NSAIDs alone for 4 weeks** | Completely inappropriate; active nephritis with RBC casts requires urgent evaluation and treatment, not watchful waiting | ## Clinical Pearl **Clinical Pearl:** The presence of RBC casts is pathognomonic of glomerulonephritis and represents a **renal emergency** in SLE. Delaying biopsy to "observe" or starting empiric therapy without histological classification risks irreversible renal damage. Hydroxychloroquine may be started concurrently as it is safe and does not interfere with biopsy interpretation. ## When Can Biopsy Be Deferred? Biopsy may be deferred only if: - The patient is critically ill and biopsy poses unacceptable risk - Coagulopathy or thrombocytopenia makes biopsy unsafe (correct first) - Isolated microscopic hematuria without proteinuria or casts (low-grade Class I/II suspected) None of these apply here — this patient has active urinary sediment with RBC casts and 2+ proteinuria, making biopsy both safe and mandatory before escalating immunosuppression. **Reference:** Harrison's Principles of Internal Medicine, 21e, Ch. 319; ACR/EULAR SLE Management Guidelines 2019; Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Guidelines 2021.